CC BY-NC-ND 4.0 · Laryngorhinootologie 2021; 100(S 02): S307
DOI: 10.1055/s-0041-1728927
Abstracts
Salivary Glands / Thyroid Gland: Salivary Glands

Expression analysis of mRNAs of extracellular matrix components in aggressive entities of salivary gland carcinomas

M Meyer
1   Universitätsmedizin Essen, HNO, Essen
,
C Arolt
2   Institut für Pathologie, Medizinische Fakultät und Uniklinik Köln, Universität zu Köln, Köln
,
D Beutner
3   Klinik und Poliklinik für Hals-, Nasen-, und Ohrenheilkunde, Universitätsklinik Göttingen, Göttingen
,
M Odenthal
2   Institut für Pathologie, Medizinische Fakultät und Uniklinik Köln, Universität zu Köln, Köln
,
JP Klußmann
4   Klinik und Poliklinik für Hals , Nasen- und Ohrenheilkunde, Kopf- und Halschirurgie, Medizinische Fakultät und Uniklinik Köln, Universität zu Köln, Köln
,
A Quaas
2   Institut für Pathologie, Medizinische Fakultät und Uniklinik Köln, Universität zu Köln, Köln
› Author Affiliations
› Further Information
Also available at
 
 

    Introduction The composition of the extracellular matrix (ECM) plays a crucial role in tumor initiation, metastasis and resistance to therapy. In salivary gland carcinomas (SGC), the composition of the ECM is still largely unclear.

    Patients and methods The mRNA of 28 genes of the ECM at 34 SGC, including 11 adenoid cystic carcinomas (ACC), 14 mucoepidermoid carcinomas (MEC) and 9 salivary duct carcinomas (SDC) were quantitatively analyzed.

    Results Overexpression of six collagens (including COL11A1) and four glycoproteins indicated a similar ECM alteration in MEC and SDC. Conversely, ACC and MEC showed significant overexpression of COL27A1 and LAMB3, respectively. Non-hierarchical cluster analysis revealed a more specific pattern for ACC with low expression of the common gene signature. In-situ studies at the RNA and protein level confirmed these results and showed that, in contrast to MEC and SDC, ECM production in ACC results from tumor cells and not from cancer-associated fibroblasts (CAFs).

    Conclusions The study demonstrates first results on the composition of the ECM in common or SGC entities with an increased probability of recurrence and the need for systemic, possibly targeted, therapy. Changes in the ECM could provide new approaches for a personalized therapy.

    Poster-PDF A-1611.pdf

    Marga und Walter Boll-Stiftung


    #

    Conflict of interest

    Der Erstautor gibt keinen Interessenskonflikt an.

    Address for correspondence

    Priv.-Doz. Dr. med. Meyer Moritz
    Universitätsmedizin Essen, HNO
    Hufelandstraße 55
    45147 Essen

    Publication History

    Article published online:
    13 May 2021

    © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany